Form 4: Cullinan Therapeutics CLO Sells Shares for Tax Obligations

Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L Sumer, sold 3,480 shares of common stock at $9.67 per share to cover tax obligations related to restricted stock unit vesting.

Summary

• Jacquelyn L Sumer, Chief Legal Officer of Cullinan Therapeutics, Inc. (CGEM), reported a transaction involving the company's common stock.
• On December 18, 2025, Sumer sold 3,480 shares of common stock.
• The shares were sold at a price of $9.67 per share, totaling $33,651.60.
• The sale was executed to cover personal income tax obligations arising from the vesting of restricted stock units.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-planned.
• Following this transaction, Sumer beneficially owns 135,432 shares of common stock.
• The reported beneficial ownership includes 2,017 shares purchased through the company's 2021 Employee Stock Purchase Plan for the period of January 1, 2025, through June 30, 2025, which were exempt under Rule 16b-3(d) and Rule 16b-3(c).

Sentiment

Score: 6

Explanation: The transaction is a routine, pre-planned sale by an insider to cover tax obligations related to vested equity, which is a neutral event. The underlying vesting of restricted stock units is a positive for the executive, indicating earned compensation.

Positives

• The underlying event of restricted stock units vesting indicates compensation earned by the Chief Legal Officer.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-planned and routine sale rather than a discretionary one based on new information.

Future Outlook

N/A. This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

This insider transaction is a routine event for publicly traded companies, where executives often sell shares to cover tax liabilities upon the vesting of equity awards. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• This routine insider transaction has minimal direct impact on shareholders, employees, customers, suppliers, or creditors. It represents a standard compensation and tax management activity for an executive.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned sale of shares by a Chief Legal Officer to cover tax obligations associated with the vesting of restricted stock units. Such transactions are common and typically do not reflect a change in the insider's view of the company's prospects or fundamental value. Therefore, it does not provide a basis for altering an investment recommendation.

Keywords

Cullinan Therapeutics, CGEM, Insider Transaction, Form 4, Stock Sale, Chief Legal Officer, Jacquelyn L Sumer, Restricted Stock Units, Tax Obligations, 10b5-1 Plan, Employee Stock Purchase Plan